Table 4 Comparison of PPV for CNV between NIPT and NIPT-PLUS according to different pregnancy characteristic
Characteristic | Prenatal diagnostic validated by CMA in NIPT | PPV for CNV in NIPT (%) | Prenatal diagnostic validated by CMA in NIPT-PLUS | PPV for CNV in NIPT-PLUS (%) | p | ||
|---|---|---|---|---|---|---|---|
Positive | Negative | Positive | Negative | ||||
Serological screening for high or intermediate risks | 37 | 70 | 34.58 | 16 | 16 | 50.00 | 0.12 |
Serological screening for the single marker value abnormality (AFP, β-HCG,uE3) | 5 | 20 | 20.00 | 7 | 10 | 41.18 | 0.14 |
Ultrasound soft-marker abnormalities | 12 | 14 | 46.15 | 8 | 5 | 61.54 | 0.36 |
isolated advanced maternal age (≥ 35 years, AMA) | 5 | 28 | 15.15 | 6 | 17 | 26.09 | 0.31 |
Othera | 2 | 4 | 33.33 | 4 | 5 | 44.44 | 0.67 |